Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen

Summary

The plasma zymogens factor XI (fXI) and prekallikrein (PK) are activated by factor XIIa (fXIIa) during contact activation. Polyanions such as DNA and RNA may contribute to thrombosis and inflammation partly by enhancing PK and fXI activation. We examined PK and fXI activation in the presence of nucleic acids, and determine the effects of the cofactor high molecular weight kininogen (HK) on the reactions. In the absence of HK, DNA and RNA induced fXI autoactivation. Proteases known to activate fXI (fXIIa and thrombin) did not enhance this process appreciably. Nucleic acids had little effect on PK activation by fXIIa in the absence of HK. HK had significant but opposite effects on PK and fXI activation. HK enhanced fXIIa activation of PK in the presence of nucleic acids, but blocked fXI autoactivation. Thrombin and fXIIa could overcome the HK inhibitory effect on autoactivation, indicating these proteases are necessary for nucleic acid-induced fXI activation in an HK-rich environment such as plasma. In contrast to PK, which requires HK for optimal activation, fXI activation in the presence of nucleic acids depends on anion binding sites on the fXI molecule. The corresponding sites on PK are not necessary for PK activation. Our results indicate that HK functions as a cofactor for PK activation in the presence of nucleic acids in a manner consistent with classic models of contact activation. However, HK has, on balance, an inhibitory effect on nucleic acid-supported fXI activation and may function as a negative regulator of fXI activation.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Contact phase - proteases - coagulation factors

• References

• 1 Müller F, Mutch NJ, Schenk WA. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156
• 2 Morrissey JH, Choi SH, Smith SA.. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979
• 3 Kannemeier C, Shibamiya A, Nakazawa F. et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393
• 4 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885
• 5 Fischer S, Preissner KT.. Extracellular nucleic acids as novel alarm signals in the vascular system. Mediators of defense and disease. Hamostaseologie 2013; 33: 37-42
• 6 Pinegin B, Vorobjeva N, Pinegin V.. Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev 2015; 14: 633-640
• 7 Brill A, Fuchs TA, Savchenko AS. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136-144
• 8 Long AT, Kenne E, Jung R. et al. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost 2016; 14: 427-437
• 9 Schmaier AH.. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost 2016; 14: 28-39
• 10 Danese E, Montagnana M, Lippi G.. Factor XII in hemostasis and thrombosis: active player or (innocent) bystander?. Semin Thromb Hemost 2016; 42: 682-688
• 11 Wiggins RC, Bouma BN, Cochrane CG, Griffin JH.. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci USA 1977; 74: 4636-4640
• 12 Thompson RE, Mandle Jr R, Kaplan AP.. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci USA 1979; 76: 4862-4866
• 13 Revenko AS, Gao D, Crosby JR. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311
• 14 Renné T, Pozgajová M, Grüner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281
• 15 Cheng Q, Tucker EI, Pine MS. et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981-3989
• 16 Matafonov A, Leung PY, Gailani AE. et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-1746
• 17 Bird JE, Smith PL, Wang X. et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-1150
• 18 Stavrou EX, Fang C, Merkulova A. et al. Reduced thrombosis in Klkb1-/-mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood 2015; 125: 710-719
• 19 Merkulov S, Zhang WM, Komar AA. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281
• 20 Wendel HP, Jones DW, Gallimore MJ.. FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery. Immunopharmacology 1999; 45: 141-144
• 21 Plötz FB, van Oeveren W, Bartlett RH, Wildevuur CR.. Blood activation during neonatal extracorporeal life support. J Thorac Cardiovasc Surg 1993; 105: 823-832
• 22 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI.. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 Suppl (01) S72-81
• 23 Gailani D, Bane CE, Gruber A.. Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost 2015; 13: 1383-1395
• 24 Fujikawa K, Chung DW, Hendrickson LE, Davie EW.. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-2424
• 25 Ponczek MB, Gailani D, Doolittle RF.. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 6: 1876-1883
• 26 Naito K, Fujikawa K.. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-7358
• 27 Gailani D, Broze Jr. GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912
• 28 von dem Borne PA, Mosnier LO, Tans G, Meijers JC, Bouma BN.. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78: 834-839
• 29 Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D.. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-458
• 30 Matafonov A, Sarilla S, Sun MF. et al. Activation of factor XI by products of prothrombin activation. Blood 2011; 118: 437-445
• 31 Choi SH, Smith SA, Morrissey JH.. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970
• 32 Geng Y, Verhamme IM, Smith SB. et al. The dimeric structure of factor XI and zymogen activation. Blood 2013; 121: 3962-3969
• 33 Gould TJ, Vu TT, Swystun LL. et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 2014; 34: 1977-1984
• 34 Tucker EI, Marzec UM, White TC. et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113: 936-944
• 35 Kokoye Y, Ivanov I, Cheng Q. et al. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb Res 2016; 140: 118-124
• 36 Geng Y, Verhamme IM, Messer A. et al. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem 2012; 287: 38200-38209
• 37 Geng Y, Verhamme IM, Smith SA. et al. Factor XI anion-binding sites are required for productive interactions with polyphosphate. J Thromb Haemost 2013; 11: 2020-2028
• 38 Zhao M, Abdel-Razek T, Sun MF, Gailani D.. Characterization of a heparin binding site on the heavy chain of factor XI. J Biol Chem 1998; 273: 31153-31159
• 39 Yang L, Sun MF, Gailani D, Rezaie AR.. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry 2009; 48: 1517-1524
• 40 Gailani D, Broze Jr. GJ. Effects of glycosaminoglycans on factor XI activation by thrombin. Blood Coagul Fibrinolysis 1993; 4: 15-20
• 41 Thompson RE, Mandle Jr R, Kaplan AP.. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-1380
• 42 Scott CF, Silver LD, Purdon AD, Colman RW.. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function J Biol Chem 1985; 260: 10856-10863
• 43 Vu TT, Leslie BA, Stafford AR. et al. Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. Thromb Haemost 2016; 115: 89-98
• 44 Gansler J, Jaax M, Leiting S. et al. Structural requirements for the procoagulant activity of nucleic acids. PLoS One 2012; 7: e50399
• 45 Nakazawa F, Kannemeier C, Shibamiya A. et al. Extracellular RNA is a natural cofactor for the auto-activation of Factor VII-activating protease (FSAP). Biochem J 2005; 385: 831-838
• 46 Gailani D, Broze Jr. GJ. Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993; 19: 396-404
• 47 Wheeler AP, Gailani D.. Why factor XI is a clinical concern. Expert Rev Hematol 2016; 9: 629-637